Aspirin Shows Promise in Reducing Colorectal Cancer Recurrence in Patients with Genetic Mutations
A recent study led by researchers at Karolinska Institutet and Karolinska University Hospital in Sweden has found that a daily low dose of aspirin may significantly reduce the recurrence of colorectal cancer in patients whose tumors carry specific genetic changes. The study, known as ALASCCA, involved more than 3,500 patients across Sweden, Norway, Denmark, and Finland. It focused on alterations in the PI3K signaling pathway, which is crucial for cell growth and survival. Patients with these genetic mutations who took aspirin had a lower recurrence rate of 7.7% compared to 14.1% in the placebo group. The study highlights aspirin's potential as a precision medicine treatment, offering a cost-effective and accessible option for cancer care. 
